Cart
sales@molnova.com
Propargyl-PEG3-amine
CAS No. 932741-19-0
Propargyl-PEG3-amine( —— )
Catalog No. M33554 CAS No. 932741-19-0
Propargyl-PEG3-amine (Propargyl-PEG3-NH2) is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 29 | In Stock |
|
| 100MG | 47 | In Stock |
|
| 500MG | 111 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePropargyl-PEG3-amine
-
NoteResearch use only, not for human use.
-
Brief DescriptionPropargyl-PEG3-amine (Propargyl-PEG3-NH2) is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.
-
DescriptionPropargyl-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Propargyl-PEG3-amine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC Linker
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number932741-19-0
-
Formula Weight187.24
-
Molecular FormulaC9H17NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC#CCOCCOCCOCCN
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562?
molnova catalog
related products
-
Amino-PEG11-amine
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.
-
PAC
PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation.
-
THAL-SNS-032
THAL-SNS-032 is a novel CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).
